SGLT-2 inhibitors for people with type 2 diabetes.

Abstract

Evidence that sodium-glucose co-transporter-2 inhibitors (SGLT2i) can reduce cardiovascular risk—with trials showing reductions in cardiovascular death, myocardial infarction, and stroke—would suggest they have much to offer in the care of patients with type 2 diabetes at high risk of cardiovascular events. But should they be used in patients at low risk?...